Literature DB >> 22467887

The impact of hematocrit on fibrin clot formation assessed by rotational thromboelastometry.

Satoru Ogawa1, Fania Szlam, Daniel Bolliger, Takashi Nishimura, Edward P Chen, Kenichi A Tanaka.   

Abstract

BACKGROUND: Rotational thromboelastometry (ROTEM®)-based FIBTEM is used perioperatively to assess the extent of fibrin polymerization in whole blood. In FIBTEM, cytochalasin D eliminates the contribution of platelets to whole blood clotting, but changing levels in fibrin(ogen) and erythrocytes may differently affect clot formation. Because dynamic changes of hematocrit are not reflected in plasma fibrinogen measurements, we hypothesized that the lack of erythrocytes in isolated plasma measurements would affect the relationship between the Clauss method and whole blood-based FIBTEM during cardiac surgery. Therefore, in the current study we investigated the influence of perioperative hematocrit changes on FIBTEM and fibrinogen measurements.
METHODS: Blood samples were collected from 6 consenting healthy volunteers. FIBTEM tests were run before and after serial in vitro dilutions of whole blood with saline or autologous plasma (5:1, 2:1, and 1:1 v/v). We then evaluated the relationship between FIBTEM-maximal clot firmness (MCF) and the Clauss fibrinogen method in relation to hematocrit values before and after cardiac surgery. Pearson correlation coefficients were determined between laboratory test results and ROTEM variables.
RESULTS: Upon in vitro hematocrit reduction, FIBTEM-MCF was progressively decreased depending on the extent of saline dilution, but it was increased by 31% after 1:1 volume replacement with autologous plasma (P < 0.05). In samples from cardiac patients (150 measurements in 50 patients), the overall correlation coefficient between FIBTEM-MCF and plasma fibrinogen was 0.80 (P < 0.001). In hemodiluted blood samples (during surgery or at intensive care unit), FIBTEM-MCF 10 mm corresponded to plasma fibrinogen levels of 200 mg/dL. In the subgroup analysis (n = 50 each), according to hematocrit levels (<25%, ≥25% to 30%, ≥30%), plasma fibrinogen levels of 200 mg/dL corresponded to 11 mm, 10 mm, and 8 mm of FIBTEM-MCF, respectively. The correlation between FIBTEM-MCF and plasma fibrinogen was higher at lower hematocrit (<25%) than at higher hematocrit (>30%) (r = 0.88 and 0.67, respectively).
CONCLUSIONS: Perioperative changes in hematocrit affect the correlation between plasma fibrinogen levels and FIBTEM-MCF values. The higher correlation between FIBTEM-MCF and plasma fibrinogen with lower hematocrit (<25%) indicates that FIBTEM is a practical method to determine the need for fibrinogen replacement in bleeding patients who typically develop perioperative anemia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22467887     DOI: 10.1213/ANE.0b013e31824d523b

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  13 in total

1.  [Early viscoelasticity-based coagulation therapy for severely injured bleeding patients: Report of the consensus group on the consensus conference 2014 for formulation of S2k guidelines].

Authors:  M Maegele; K Inaba; S Rizoli; P Veigas; J Callum; R Davenport; M Fröhlich; J Hess
Journal:  Anaesthesist       Date:  2015-10       Impact factor: 1.041

2.  In Vivo Effects of Balanced Crystalloid or Gelatine Infusions on Functional Parameters of Coagulation and Fibrinolysis: A Prospective Randomized Crossover Study.

Authors:  Agnieszka Wiórek; Piotr K Mazur; Elżbieta Żurawska; Łukasz J Krzych
Journal:  J Pers Med       Date:  2022-05-31

3.  Design and Utility of a Point-of-Care Microfluidic Platform to Assess Hematocrit and Blood Coagulation.

Authors:  Jevgenia Zilberman-Rudenko; Rachel M White; Dmitriy A Zilberman; Hari H S Lakshmanan; Rachel A Rigg; Joseph J Shatzel; Jeevan Maddala; Owen J T McCarty
Journal:  Cell Mol Bioeng       Date:  2018-07-19       Impact factor: 2.321

4.  Prediction of Post-Weaning Fibrinogen Status during Cardiopulmonary Bypass: An Observational Study in 110 Patients.

Authors:  Gabor Erdoes; Germaine Gerster; Giuseppe Colucci; Heiko Kaiser; Lorenzo Alberio; Balthasar Eberle
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

5.  Predictive value of rotational thromboelastometry during cardiopulmonary bypass for thrombocytopenia and hypofibrinogenemia after weaning of cardiopulmonary bypass.

Authors:  Sung-Mi Ji; Sung-Hoon Kim; Jae-Sik Nam; Hye-Joo Yun; Jeong-Hyun Choi; Eun-Ho Lee; In-Cheol Choi
Journal:  Korean J Anesthesiol       Date:  2015-05-28

6.  Correction of hypothermic and dilutional coagulopathy with concentrates of fibrinogen and factor XIII: an in vitro study with ROTEM.

Authors:  Dag Winstedt; Owain D Thomas; Fredrik Nilsson; Knut Olanders; Ulf Schött
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2014-12-16       Impact factor: 2.953

7.  Therapeutic plasma exchange in heart transplantation: role of coagulation assessment with thromboelastometry.

Authors:  Andrew Crabbe; John S McNeil; Seema P Deshpande; Zachary Kon; Si M Pham; Kenichi A Tanaka
Journal:  JA Clin Rep       Date:  2016-10-19

8.  Simultaneous assessment of blood coagulation and hematocrit levels in dielectric blood coagulometry.

Authors:  Yoshihito Hayashi; Marc-Aurèle Brun; Kenzo Machida; Seungmin Lee; Aya Murata; Shinji Omori; Hidetoshi Uchiyama; Yoshinori Inoue; Toshifumi Kudo; Takahiro Toyofuku; Masayuki Nagasawa; Isao Uchimura; Tomomasa Nakamura; Takeshi Muneta
Journal:  Biorheology       Date:  2017       Impact factor: 1.875

9.  Free oscillation rheometry monitoring of haemodilution and hypothermia and correction with fibrinogen and factor XIII concentrates.

Authors:  Dag Winstedt; Nahreen Tynngård; Knut Olanders; Ulf Schött
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2013-03-22       Impact factor: 2.953

10.  Evaluation of hemostatic abnormalities in canine spirocercosis and its association with systemic inflammation.

Authors:  P Pazzi; A Goddard; A T Kristensen; E Dvir
Journal:  J Vet Intern Med       Date:  2013-10-21       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.